Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.
Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, van Loon J, de Vries L, Cavé H, Acquaviva C, Lawler M, Crampe M, Serra A, Saglio B, Colnaghi F, Biondi A, van Dongen JJ, van der Burg M, Gonzalez M, Alcoceba M, Barbany G, Hermanson M, Roosnek E, Steward C, Harvey J, Frommlet F, Bader P. Lion T, et al. Among authors: van dongen jj, van loon j, van der burg m. Leukemia. 2012 Aug;26(8):1821-8. doi: 10.1038/leu.2012.66. Epub 2012 Mar 7. Leukemia. 2012. PMID: 22395360
Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeats.
van der Burg M, Kreyenberg H, Willasch A, Barendregt BH, Preuner S, Watzinger F, Lion T, Roosnek E, Harvey J, Alcoceba M, Díaz MG, Bader P, van Dongen JJ; EU-supported EuroChimerism Consortium project QLRT-2001-01485. van der Burg M, et al. Among authors: van dongen jj. Leukemia. 2011 Sep;25(9):1467-70. doi: 10.1038/leu.2011.118. Epub 2011 Jun 17. Leukemia. 2011. PMID: 21681189
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW. Lankester AC, et al. Among authors: van der velden vh, van dongen jj, van tol mj, van wering er. Leukemia. 2010 Aug;24(8):1462-9. doi: 10.1038/leu.2010.133. Epub 2010 Jun 10. Leukemia. 2010. PMID: 20535148
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J. Beillard E, et al. Among authors: van der velden vh, van dongen jj, van der schoot e. Leukemia. 2003 Dec;17(12):2474-86. doi: 10.1038/sj.leu.2403136. Leukemia. 2003. PMID: 14562124
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, van Dongen JJ. Pongers-Willemse MJ, et al. Among authors: van dongen jj. Leukemia. 1999 Jan;13(1):110-8. doi: 10.1038/sj.leu.2401245. Leukemia. 1999. PMID: 10049045
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ. Gabert J, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2003 Dec;17(12):2318-57. doi: 10.1038/sj.leu.2403135. Leukemia. 2003. PMID: 14562125 Review.
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, van Dongen JJM, Ottmann OG. Pfeifer H, et al. Leukemia. 2020 Jul;34(7):1970. doi: 10.1038/s41375-020-0707-2. Leukemia. 2020. PMID: 31937894
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ; European Study Group on MRD detection in ALL (ESG-MRD-ALL). van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce. Leukemia. 2007 Apr;21(4):604-11. doi: 10.1038/sj.leu.2404586. Epub 2007 Feb 8. Leukemia. 2007. PMID: 17287850
585 results